We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days) in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2 drugs. The mean time to defervescence (± standard deviation) was 46.2 ± 36.4 h in the clarithromycin group and 39.3 ± 31.3 h in the azithromycin group. These differences were not statistically significant and both drugs were equally well-tolerated. Clarithromycin and azithromycin could be acceptable therapeutic alternatives to chloramphenicol and tetracyclines for children aged ≥8 years with Mediterranean spotted fever. Azithromycin, because it has a long half-life, offers the advantages of administration in a single daily dose and a shorter duration of therapy, which could increase compliance in children.
Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: A randomized controlled trial / A. Cascio, C. Colomba, S. Antinori, D.L. Paterson, L. Titone. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 34:2(2002), pp. 154-158. (Intervento presentato al 11. convegno European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) tenutosi a Istanbul nel 2001) [10.1086/338068].
Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: A randomized controlled trial
S. AntinoriWriting – Review & Editing
;
2002
Abstract
We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days) in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2 drugs. The mean time to defervescence (± standard deviation) was 46.2 ± 36.4 h in the clarithromycin group and 39.3 ± 31.3 h in the azithromycin group. These differences were not statistically significant and both drugs were equally well-tolerated. Clarithromycin and azithromycin could be acceptable therapeutic alternatives to chloramphenicol and tetracyclines for children aged ≥8 years with Mediterranean spotted fever. Azithromycin, because it has a long half-life, offers the advantages of administration in a single daily dose and a shorter duration of therapy, which could increase compliance in children.File | Dimensione | Formato | |
---|---|---|---|
34-2-154.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
113.93 kB
Formato
Adobe PDF
|
113.93 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.